BMO Capital Maintains Outperform on Ingevity, Lowers Price Target to $72
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
BMO Capital analyst John McNulty maintains Ingevity (NYSE:NGVT) with a Outperform and lowers the price target from $85 to $72.
BMO Capital analyst John McNulty maintains Ingevity (NYSE:NGVT) with a Outperform and lowers the price target from $85 to $72.
